Heng Chen

Heng Chen is a Senior Manager in Biostatistics at Gilead Sciences since January 2022, overseeing Phase 1/2 clinical trials in autoimmune diseases, spearheading study design, statistical analyses, and regulatory submissions, including a TQT waiver to the FDA. Heng also supports Phase 3 clinical trial designs for NASH and COVID-19, while leading a working group focused on causal learning and machine learning methodologies to enhance precision medicine. Previously, Heng served as a Manager in Biostatistics, conducting research in clinical trials and causal inference, and held a postdoctoral research fellow position at Fred Hutch, specializing in statistical learning and high-dimensional omics data. Early experience included data analysis for medical research at UT Southwestern Medical Center and developing deep learning algorithms as a summer research intern. Heng holds a PhD in Statistics from Southern Methodist University and a BS in Statistics from Tongji University.